BRNS vs TGT · $38.2M cap vs P/E 17, rev $51.98B
Barinthus Biotherapeutics plc (BRNS) versus Target Corporation (TGT) — a side-by-side from cached financials, not a winner call.
Barinthus Biotherapeutics plc (BRNS) is a biotechnology company listed on US.
Target Corporation (TGT) is a discount stores company listed on NYSE. It is led by Michael J. Fiddelke.
Latest reported BRNS revenue for 2025-09-30 was $0. Net income was -$14.6M. BRNS currently screens at market cap $38.2M.
Latest reported TGT revenue for 2026-08-01 was $51.98B. Net income was $2.66B. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
BRNS currently screens at market cap $38.2M. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
Not investment advice. Open the BRNS and TGT stock pages for the full models.
Not investment advice.